How should I schedule the use of Hycoscan hyaluronic‑acid artificial tears and Restasis (cyclosporine 0.05% ophthalmic emulsion)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Schedule Hycoscan and Restasis

Use Restasis (cyclosporine 0.05%) twice daily approximately 12 hours apart, and wait at least 15 minutes before instilling Hycoscan (hyaluronic acid artificial tears), which can then be used as frequently as needed throughout the day.

Scheduling Algorithm

Step 1: Restasis Administration

  • Instill Restasis twice daily (morning and evening, approximately 12 hours apart) 1
  • Invert the vial several times before use to ensure uniform emulsion 1
  • Use immediately after opening and discard the vial 1

Step 2: Wait Period

  • Wait 15 minutes after Restasis instillation before using any other eye drops 1
  • This interval is critical to prevent dilution of cyclosporine and ensure adequate ocular surface contact time

Step 3: Artificial Tear Use

  • After the 15-minute waiting period, instill Hycoscan (hyaluronic acid artificial tears)
  • Use as frequently as needed for symptom relief—typically 4+ times daily for moderate dry eye 2
  • Since you're using tears more than 4 times daily, preservative-free formulations like Hycoscan are appropriate 2

Practical Daily Schedule Example

Morning:

  • 8:00 AM: Restasis
  • 8:15 AM or later: Hycoscan (first dose)
  • Continue Hycoscan throughout the day as needed

Evening:

  • 8:00 PM: Restasis
  • 8:15 PM or later: Hycoscan (if needed)

Rationale for This Approach

The 2024 Dry Eye Syndrome Preferred Practice Pattern guidelines emphasize that anti-inflammatory therapies like cyclosporine should be used in addition to aqueous enhancement therapies (artificial tears) for moderate dry eye 2. The combination addresses both the inflammatory component (Restasis) and symptomatic relief (Hycoscan).

Research supports this combined approach: a 2006 study demonstrated that the choice of concomitant artificial tear therapy significantly affects outcomes when used with Restasis, with both therapies being compatible 3. The FDA label explicitly states that Restasis can be used concomitantly with artificial tears when the 15-minute interval is observed 1.

Important Caveats

  • Do not use Restasis while wearing contact lenses—remove lenses before instillation and wait 15 minutes before reinserting 1
  • Ocular burning occurs in approximately 17% of patients using cyclosporine; this typically improves with continued use 2
  • Full therapeutic effect of Restasis may take 3-6 months to develop, though some improvement may be seen earlier 2
  • The hyaluronic acid in Hycoscan provides additional benefits beyond simple lubrication, including anti-inflammatory properties and epithelial healing support 4

Long-term Considerations

After 12 months of twice-daily Restasis therapy, some patients can reduce to once-daily dosing without losing beneficial effects 2. However, this decision should be made based on clinical response and disease severity. Continue the artificial tears as needed regardless of Restasis frequency adjustments.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.